Humoral response to a third injection of BNT162b2 vaccine in patients on maintenance haemodialysis.
BNT162b2 vaccine
COVID-19
SARS-Cov-2
haemodialysis
immunogenicity
Journal
Clinical kidney journal
ISSN: 2048-8505
Titre abrégé: Clin Kidney J
Pays: England
ID NLM: 101579321
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
received:
24
06
2021
accepted:
27
07
2021
entrez:
10
11
2021
pubmed:
11
11
2021
medline:
11
11
2021
Statut:
epublish
Résumé
Humoral response against sudden acute respiratory syndrome coronavirus 2 (SARS-CoV-2) after two doses of BNT162b2 (Pfizer-BioNTech) has been proven to be less intense in maintenance dialysis patients as compared with healthy subjects, leading the French authorities to recommend a third injection in this population. Here we investigated the response to the third injection in two cohorts of haemodialysis (HD) patients. Data from two prospective observational cohorts were collected. In the first ('systematic') cohort, patients from two HD centres ( In the systematic cohort, anti-S IgG was found in 83.3 and 92.4% of patients after the second and third doses of BNT162b2, respectively. In this cohort, 6/11 (54.5%) and 20/21 (95.2%) patients switched from non-responder to low responder and from low responder to high responder, respectively. In low and high responders to two doses, 50/55 (90.9%) at least doubled their anti-S IgG titre. Similar trends were observed in the conditional cohort. In maintenance HD patients, humoral response against SARS-CoV-2 was boosted after a third dose of BNT162b2, allowing seroconversion in more than half of non-responders. These data may support an intensified vaccination protocol with a third dose of BNT162b2 in dialysis patients.
Sections du résumé
BACKGROUND
BACKGROUND
Humoral response against sudden acute respiratory syndrome coronavirus 2 (SARS-CoV-2) after two doses of BNT162b2 (Pfizer-BioNTech) has been proven to be less intense in maintenance dialysis patients as compared with healthy subjects, leading the French authorities to recommend a third injection in this population. Here we investigated the response to the third injection in two cohorts of haemodialysis (HD) patients.
METHODS
METHODS
Data from two prospective observational cohorts were collected. In the first ('systematic') cohort, patients from two HD centres (
RESULTS
RESULTS
In the systematic cohort, anti-S IgG was found in 83.3 and 92.4% of patients after the second and third doses of BNT162b2, respectively. In this cohort, 6/11 (54.5%) and 20/21 (95.2%) patients switched from non-responder to low responder and from low responder to high responder, respectively. In low and high responders to two doses, 50/55 (90.9%) at least doubled their anti-S IgG titre. Similar trends were observed in the conditional cohort.
CONCLUSIONS
CONCLUSIONS
In maintenance HD patients, humoral response against SARS-CoV-2 was boosted after a third dose of BNT162b2, allowing seroconversion in more than half of non-responders. These data may support an intensified vaccination protocol with a third dose of BNT162b2 in dialysis patients.
Identifiants
pubmed: 34754430
doi: 10.1093/ckj/sfab152
pii: sfab152
pmc: PMC8573007
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2349-2355Informations de copyright
© The Author(s) 2021. Published by Oxford University Press on behalf of ERA-EDTA.
Références
J Clin Invest. 2021 Jul 15;131(14):
pubmed: 34101623
Kidney Int. 2021 Jun;99(6):1494-1496
pubmed: 33887320
Sci Immunol. 2021 Jun 15;6(60):
pubmed: 34131023
CMAJ. 2021 May 31;193(22):E793-E800
pubmed: 33980499
Nephrol Dial Transplant. 2021 Apr 11;:
pubmed: 33839785
J Am Soc Nephrol. 2021 Sep;32(9):2147-2152
pubmed: 34112706
Kidney Int. 2021 Jun;99(6):1490-1492
pubmed: 33887317
Nephrol Dial Transplant. 2021 Aug 27;36(9):1709-1716
pubmed: 33999200
Clin J Am Soc Nephrol. 2021 Jul;16(7):1037-1042
pubmed: 33824157
Eur J Clin Invest. 2021 Jul;51(7):e13573
pubmed: 33870493
Nephrol Dial Transplant. 2021 Mar 29;36(4):571-574
pubmed: 33475137
J Am Soc Nephrol. 2021 Sep;32(9):2153-2158
pubmed: 34135083
J Nephrol. 2021 Aug;34(4):975-983
pubmed: 34050904
Nat Rev Nephrol. 2021 Feb;17(2):81-82
pubmed: 33257872
J Am Soc Nephrol. 2021 Oct;32(10):2435-2438
pubmed: 34117129
J Am Soc Nephrol. 2021 Nov;32(11):2735-2742
pubmed: 34348908
Nephrol Dial Transplant. 2021 Aug 27;36(9):1756-1757
pubmed: 34450646
Kidney Int. 2021 Jun;99(6):1496-1498
pubmed: 33887318
Nephrol Dial Transplant. 2021 Aug 27;36(9):1704-1709
pubmed: 34057463
Kidney Int. 2020 Dec;98(6):1540-1548
pubmed: 32979369
Clin J Am Soc Nephrol. 2021 Aug;16(8):1258-1260
pubmed: 34031182
Clin J Am Soc Nephrol. 2021 Jul;16(7):1073-1082
pubmed: 34031181
Kidney Int. 2021 Apr;99(4):1022-1023
pubmed: 33485912
J Am Soc Nephrol. 2021 May 3;32(5):1033-1036
pubmed: 33637518
Vaccines (Basel). 2021 Apr 08;9(4):
pubmed: 33918085